Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Bruchertseifer

Showing results (1-10 of 153) with videos related to

Pageof 16
Sort By:
Journal of Medical Imaging and Radiation Sciences|August 14, 2019
Development of Targeted Alpha Therapy from Bench to BedsideAlfred Morgenstern, Frank Bruchertseifer
Seminars in Nuclear Medicine|March 17, 2020
Supply and Clinical Application of Actinium-225 and Bismuth-213Alfred Morgenstern, Christos Apostolidis, Frank Bruchertseifer
Current Radiopharmaceuticals|December 29, 2011
Targeted alpha therapy with 213BiAlfred Morgenstern, Frank Bruchertseifer, Christos Apostolidis
Current Radiopharmaceuticals|May 31, 2012
Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopesAlfred Morgenstern, Frank Bruchertseifer, Christos Apostolidis
Journal of Labelled Compounds & Radiopharmaceuticals|August 2, 2019
Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demandFrank Bruchertseifer, Alban Kellerbauer, Rikard Malmbeck, et al.
Journal of Inorganic Biochemistry|October 6, 2009
Spectroscopic study of the interaction of U(VI) with transferrin and albumin for speciation of U(VI) under blood serum conditionsGilles Montavon, Christos Apostolidis, Frank Bruchertseifer, et al.
Journal of Nanoparticle Research : an Interdisciplinary Forum for Nanoscale Science and Technology|December 6, 2013
Functionalized NaA nanozeolites labeled with <sup>224,225</sup>Ra for targeted alpha therapyAgata Piotrowska, Edyta Leszczuk, Frank Bruchertseifer, et al.
Molecular Pharmaceutics|March 6, 2018
Evaluation of an Anti-HER2 Nanobody Labeled with <sup>225</sup>Ac for Targeted α-Particle Therapy of CancerMarek Pruszynski, Matthias D'Huyvetter, Frank Bruchertseifer, et al.
Frontiers in Medicine|January 2, 2023
Targeted alpha therapy for glioblastomaJolanta Kunikowska, Alfred Morgenstern, Kacper Pełka, et al.
Annals of Translational Medicine|August 9, 2024
Design of <sup>225</sup>Ac-PSMA for targeted alpha therapy in prostate cancerKalevi Kairemo, Mankgopo Kgatle, Frank Bruchertseifer, et al.
Pageof 16

Showing results (1-10 of 153) with videos related to

Sort By:
Pageof 16
Journal of Medical Imaging and Radiation Sciences|August 14, 2019
Development of Targeted Alpha Therapy from Bench to BedsideAlfred Morgenstern, Frank Bruchertseifer
Seminars in Nuclear Medicine|March 17, 2020
Supply and Clinical Application of Actinium-225 and Bismuth-213Alfred Morgenstern, Christos Apostolidis, Frank Bruchertseifer
Current Radiopharmaceuticals|December 29, 2011
Targeted alpha therapy with 213BiAlfred Morgenstern, Frank Bruchertseifer, Christos Apostolidis
Current Radiopharmaceuticals|May 31, 2012
Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopesAlfred Morgenstern, Frank Bruchertseifer, Christos Apostolidis
Journal of Labelled Compounds & Radiopharmaceuticals|August 2, 2019
Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demandFrank Bruchertseifer, Alban Kellerbauer, Rikard Malmbeck, et al.
Journal of Inorganic Biochemistry|October 6, 2009
Spectroscopic study of the interaction of U(VI) with transferrin and albumin for speciation of U(VI) under blood serum conditionsGilles Montavon, Christos Apostolidis, Frank Bruchertseifer, et al.
Journal of Nanoparticle Research : an Interdisciplinary Forum for Nanoscale Science and Technology|December 6, 2013
Functionalized NaA nanozeolites labeled with <sup>224,225</sup>Ra for targeted alpha therapyAgata Piotrowska, Edyta Leszczuk, Frank Bruchertseifer, et al.
Molecular Pharmaceutics|March 6, 2018
Evaluation of an Anti-HER2 Nanobody Labeled with <sup>225</sup>Ac for Targeted α-Particle Therapy of CancerMarek Pruszynski, Matthias D'Huyvetter, Frank Bruchertseifer, et al.
Frontiers in Medicine|January 2, 2023
Targeted alpha therapy for glioblastomaJolanta Kunikowska, Alfred Morgenstern, Kacper Pełka, et al.
Annals of Translational Medicine|August 9, 2024
Design of <sup>225</sup>Ac-PSMA for targeted alpha therapy in prostate cancerKalevi Kairemo, Mankgopo Kgatle, Frank Bruchertseifer, et al.
Pageof 16